Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Refametinib + Sorafenib in KRAS/NRAS-mutant HCC
CTR20140453Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of refametinib in hepatocellular carcinoma (HCC), sponsored by Bayer. Started Nov 2014; status: completed.
02
Drugs
refametinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20140453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140453.